Why Is REPLIMUNE GROUP INC (REPL) Stock Moving Today?
By the Top Tier Newswire AI Desk · August 3, 2026 at 1:13 AM ET · reviewed against 1 wire stories
REPLIMUNE GROUP INC (REPL) is drawing unusual attention today. Our newswire has captured 1 story on REPL across 1 source in the last 36 hours, with AI sentiment reading bullish (avg 73/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
REPLIMUNE GROUP INC stock is moving today, climbing toward a 52-week high amid renewed optimism for its skin cancer therapy following a favorable FDA panel vote. The stock's recent surge reflects a broader wave of Wall Street optimism and positive company catalysts, with shares now trading near the top of their 52-week range of $1.50 to $12.50. The stock has also drawn attention from analysts, including Wedbush, which raised its price target to $12 while maintaining a neutral stance.
What Happened
The recent FDA panel vote has reignited hopes for Replimune's skin cancer therapy, offering a key catalyst for the stock's upward movement. This comes as the company remains unprofitable, with a trailing twelve-month earnings per share of -3.38 and a market cap of $940.4 million. The stock's beta of 0.87 suggests it is slightly less volatile than the broader market. Meanwhile, Wedbush's updated price target of $12, though neutral in tone, has added to the stock's visibility. The positive FDA news appears to have been a primary driver, with the broader health care sector also showing movement in pre-market and intraday sessions.
What The Data Shows
Insider transactions show recent selling activity, with Chief Commercial Officer Christopher Sarchi selling shares on June 1, 2026. Over the last 90 days, there have been no insider buys and one sell totaling $111,000. The most recent filing was on June 3, 2026. The stock has seen limited social chatter, with no posts in the last 24 hours and only two in the last seven. No unusual options activity or significant volume spikes have been reported.
What To Watch
With no earnings date provided, investors may want to monitor the breadth of analyst coverage and any further developments in Replimune's pipeline, particularly regarding its skin cancer therapy. Continued FDA-related news or updated guidance could further influence the stock's trajectory.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
REPL · Aug 3 session (5-min) · +6.03% vs prior close · updated 8:55 PM ETAI sentiment, last 36h · averaged over 1 story · 73/100 bullish
The headlines behind the move
Story flow · 1 story on the wire, last 36h · hover or tap a dot for the headline
7d agoStocktwits NewsBULLISH 73General
Why Did REPL, SNOW, NET Stocks Surge To 52-Week Highs Last Week?
Replimune, Snowflake, and Cloudflare shares surged to annual highs last week amid a series of positive company catalysts, Wall Street optimism, and earnings anticipation.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →